Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking

Completed · Phase 3 · Has a placebo group

Conditions studied: Smoking Cessation

In brief

The primary purpose of this study is to determine whether or not varenicline will help people with cardiovascular disease quit smoking and to confirm it is safe in these patients.

Key facts

Study ID

NCT00282984

Run by

Pfizer

People needed

714

Starts

2006-02-01

Expected to finish

2008-08-01

Last updated by the study team

2017-04-05

Who can join

Age: 35 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must have stable, documented cardiovascular disease (including at least one of the following diagnosed > 2 months prior to the Screening visit - angina, myocardial infarction (MI), revascularization, transient ischemic attack (TIA), and peripheral vascular disease (PVD).
• Participants that smoke > 10 cigarettes / day.

You may not qualify if…

• Participants with unstable cardiovascular disease
• Cardiovascular events in the past 2 months
• Moderate or severe chronic obstructive pulmonary disease (COPD)

Where it is running

• Pfizer Investigational Site — Hartford, Connecticut, United States
• Pfizer Investigational Site — Boston, Massachusetts, United States
• Pfizer Investigational Site — Madison, Wisconsin, United States
• Pfizer Investigational Site — Capital Federal, Buenos Aires, Argentina
• Pfizer Investigational Site — Ciudad de Buenos Aires, Buenos Aires, Argentina
• Pfizer Investigational Site — Concord, New South Wales, Australia
• Pfizer Investigational Site — Herston, Queensland, Australia
• Pfizer Investigational Site — Porto Alegre, Rio Grande do Sul, Brazil
• Pfizer Investigational Site — São Paulo, São Paulo, Brazil
• Pfizer Investigational Site — London, Ontario, Canada
• Pfizer Investigational Site — Ottawa, Ontario, Canada
• Pfizer Investigational Site — Drummondville, Quebec, Canada
• Pfizer Investigational Site — Québec, Quebec, Canada
• Pfizer Investigational Site — Brno, Czechia
• Pfizer Investigational Site — Prague, Czechia
• Pfizer Investigational Site — Aarhus C, Denmark
• Pfizer Investigational Site — Hellerup, Denmark
• Pfizer Investigational Site — Caen, France
• Pfizer Investigational Site — Marseille, France
• Pfizer Investigational Site — Toulouse, France
• Pfizer Investigational Site — Berlin, Germany
• Pfizer Investigational Site — Göttingen, Germany
• Pfizer Investigational Site — Tübingen, Germany
• Pfizer Investigational Site — Athens, Greece
• Pfizer Investigational Site — Pireaus, Greece

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.